Inhibrx Biosciences (INBX) Financials: Revenue & Earnings
INBX$72.73-22.93 -23.97%
$1.07B
Market Cap
-10.52
P/E
27.24
Forward P/E
69
Score
Inhibrx Biosciences (INBX) Financials: Revenue & Earnings
INBX price $72.73 -22.93 -23.97%
- Ticker
- INBX
- Price
- $72.73
- Change
- -22.93 -23.97%
- Market cap ?
- $1.07B
- P/E ?
- -10.52
- Forward P/E ?
- 27.24
- Dividend yield ?
- 0.00%
- Beta ?
- 3.82
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 69
- Value
- 49
- Quality
- 58
- Growth
- 100
Stocklytics score rationale: value 49, quality 58, growth 100.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 6667000 | 8391000 | 8595000 | 9093000 | 12808000 | 7125000 | 2192000 | 1800000 | 200000 | 1300000 |
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is…
Fair value
INBX fair value $52.92. Price $72.73. Price is 37% above fair value.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 152.02K. Growth 20.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 12.00% (beta 2.0). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 14.72M. Net debt -17.21M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-13 | — | -2.45 | — | 1.90M |
| 2026-08-13 | -2.34 | -2.28 | — | — |
| 2026-05-14 | -2.15 | -2.37 | — | — |
| 2026-03-19 | -2.11 | -2.08 | — | 1.11M |
| 2025-11-14 | -2.28 | -2.08 | — | — |
| 2025-08-13 | -1.85 | -2.92 | 1.30M | — |
| 2025-05-14 | -2.80 | -2.55 | — | — |
| 2025-03-17 | -3.09 | -2.88 | 100.00K | — |
| 2024-11-14 | -2.84 | -3.06 | — | — |
| 2024-08-13 | 125.48 | -3.60 | 100.00K | — |
| 2024-06-03 | -1.44 | -1.04 | — | 50.00K |
| 2024-02-28 | -1.73 | -1.07 | 1.63M | 50.00K |
| 2023-11-09 | -1.10 | -1.01 | 119.00K | 50.00K |
| 2023-08-07 | -1.08 | -1.02 | 30.00K | — |
| 2023-05-08 | -1.12 | -0.84 | 17.00K | 150.00K |
| 2023-03-06 | -0.95 | -0.80 | 274.00K | 994.00K |
| 2022-11-07 | -0.90 | -1.01 | 278.00K | 633.33K |
| 2022-08-08 | -0.97 | -0.84 | 711.00K | 1.07M |
| 2022-05-09 | -0.80 | -0.62 | 915.00K | 1.10M |
| 2022-02-28 | -0.55 | -0.53 | 2.84M | 1.21M |
| 2021-11-09 | -0.54 | -0.57 | 2.51M | 1.50M |
| 2021-08-09 | -0.55 | -0.51 | 918.00K | 820.00K |
| 2021-05-13 | -0.51 | -0.61 | 863.00K | 1.01M |
| 2021-03-12 | -0.47 | -0.50 | 2.78M | — |
| 2020-11-13 | -0.77 | -0.60 | 5.83M | — |
| 2020-08-19 | -0.70 | — | 872.00K | — |
| 2020-06-30 | -0.50 | — | 3.33M | — |
| 2019-12-31 | -0.57 | — | 267.00K | — |
| 2019-09-30 | -0.70 | — | 794.00K | — |
| 2019-06-30 | -0.39 | — | 1.00M | — |
| 2019-03-31 | -0.13 | — | 7.03M | — |
| 2018-12-31 | -0.24 | — | 2.27M | — |
| 2018-06-30 | -0.25 | — | 2.50M | — |
| 2018-03-31 | -0.32 | — | 2.50M | — |
| 2017-12-31 | -0.44 | — | 281.00K | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency Irregular.
Safety score 43/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. Dividend history is short. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| 2024-05-30 | $0.85 | 2024-05-30 | 2024-06-20 | Irregular |
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-14 | Lappe Mark | Buy | 100 | $85.76 | 8.58K |
| 2026-10-14 | Lappe Mark | Buy | 2.47K | $85.00 | 209.95K |
| 2026-10-14 | Lappe Mark | Buy | 2.47K | $84.07 | 207.65K |
| 2026-10-14 | Lappe Mark | Buy | 100 | $85.76 | 8.58K |
| 2026-10-14 | Lappe Mark | Buy | 2.45K | $85.00 | 208.33K |
| 2026-10-14 | Lappe Mark | Buy | 2.45K | $84.07 | 205.89K |
| 2026-09-28 | Lappe Mark | Buy | 3.00K | $101.70 | 305.11K |
| 2026-09-28 | Lappe Mark | Buy | 1.50K | $98.88 | 148.32K |
| 2026-09-25 | Lappe Mark | Buy | 2.18K | $99.60 | 216.73K |
| 2026-09-25 | Lappe Mark | Buy | 3.32K | $98.87 | 328.63K |
| 2026-09-23 | Kayyem Jon Faiz | Buy | 5.00K | $100.00 | 500.00K |
| 2026-09-16 | Kayyem Jon Faiz | Buy | 5.00K | $100.00 | 500.00K |
| 2026-09-15 | MANHARD KIMBERLY | Sell | 500 | $105.05 | 52.52K |
| 2026-09-14 | MANHARD KIMBERLY | Sell | 500 | $110.26 | 55.13K |
| 2026-09-11 | MANHARD KIMBERLY | Sell | 500 | $111.78 | 55.89K |
| 2026-09-09 | MANHARD KIMBERLY | Sell | 500 | $115.80 | 57.90K |
| 2026-09-08 | MANHARD KIMBERLY | Sell | 500 | $115.14 | 57.57K |
| 2026-09-08 | Kayyem Jon Faiz | Buy | 5.00K | $113.52 | 567.58K |
| 2026-09-08 | FORSYTH DOUGLAS | Buy | 2.50K | $114.65 | 286.62K |
| 2026-09-08 | Lappe Mark | Buy | 9.68K | $112.28 | 1.09M |
| 2026-09-08 | Lappe Mark | Buy | 1.22K | $111.88 | 136.38K |
| 2026-09-08 | Lappe Mark | Buy | 500 | $108.23 | 54.12K |
| 2026-09-08 | Lappe Mark | Buy | 1.10K | $107.12 | 117.84K |
| 2026-09-08 | Lappe Mark | Buy | 6.61K | $100.64 | 664.72K |
| 2026-09-08 | Lappe Mark | Buy | 5.89K | $99.29 | 585.34K |
| 2026-06-03 | FORSYTH DOUGLAS | Buy | 10.00K | $95.22 | 952.20K |
| 2026-06-03 | Vuori Kristiina MD | Buy | 10.00K | $95.22 | 952.20K |
| 2026-06-03 | MANHARD KIMBERLY | Buy | 10.00K | $95.22 | 952.20K |
| 2026-06-03 | Kayyem Jon Faiz | Buy | 10.00K | $95.22 | 952.20K |
| 2026-06-03 | Vuori Kristiina MD | Buy | 15.00K | $95.22 | 1.43M |
| 2026-06-03 | Kayyem Jon Faiz | Buy | 15.00K | $95.22 | 1.43M |
| 2026-06-03 | FORSYTH DOUGLAS | Buy | 15.00K | $95.22 | 1.43M |
| 2026-06-03 | MANHARD KIMBERLY | Buy | 15.00K | $95.22 | 1.43M |
| 2026-04-24 | Matly David | Buy | 50.00K | $129.06 | 6.45M |
| 2025-10-07 | VIKING GLOBAL INVESTORS LP | Sell | 308.64K | $32.25 | 9.95M |
| 2025-10-07 | VIKING GLOBAL INVESTORS LP | Sell | 25.04K | $32.25 | 807.60K |
| 2025-10-07 | VIKING GLOBAL INVESTORS LP | Sell | 16.32K | $32.25 | 526.16K |
| 2025-05-28 | MANHARD KIMBERLY | Buy | 15.00K | $12.91 | 193.65K |
| 2025-05-28 | Vuori Kristiina MD | Buy | 15.00K | $12.91 | 193.65K |
| 2025-05-28 | Kayyem Jon Faiz | Buy | 15.00K | $12.91 | 193.65K |
| 2025-05-28 | FORSYTH DOUGLAS | Buy | 15.00K | $12.91 | 193.65K |
| 2025-04-01 | Deck Kelly | Buy | 15.00K | $14.05 | 210.75K |
| 2025-04-01 | Matly David | Buy | 50.00K | $14.05 | 702.50K |
| 2025-04-01 | Matly David | Other | 175.00K | $15.86 | 2.78M |
| 2025-03-27 | Kayyem Jon Faiz | Sell | 90.00K | — | — |
| 2024-12-16 | Kayyem Jon Faiz | Sell | 500.00K | — | — |
| 2024-12-16 | Kayyem Jon Faiz | Buy | 250.00K | — | — |
| 2024-12-06 | Kayyem Jon Faiz | Sell | 52.00K | — | — |
| 2024-11-20 | Kayyem Jon Faiz | Buy | 18.75K | $14.19 | 266.10K |
| 2024-11-19 | Kayyem Jon Faiz | Buy | 34.84K | $14.23 | 495.71K |
| 2024-10-03 | Vuori Kristiina MD | Buy | 6.67K | $15.00 | 100.00K |
| 2024-09-16 | Lappe Mark | Buy | 13.04K | $17.13 | 223.32K |
| 2024-09-12 | Lappe Mark | Buy | 26.96K | $15.05 | 405.79K |
| 2024-09-11 | Vuori Kristiina MD | Buy | 6.46K | $15.07 | 97.31K |
| 2024-09-10 | Vuori Kristiina MD | Buy | 179 | $15.00 | 2.69K |
| 2024-09-10 | Lappe Mark | Buy | 8.50K | $15.19 | 129.12K |
| 2024-09-09 | Lappe Mark | Buy | 9.50K | $15.21 | 144.50K |
| 2024-09-06 | Lappe Mark | Buy | 26.00K | $15.29 | 397.54K |
| 2024-08-28 | MANHARD KIMBERLY | Buy | 10.00K | $13.98 | 139.80K |
| 2024-08-23 | FORSYTH DOUGLAS | Buy | 59.81K | $14.07 | 841.55K |
| 2024-08-22 | FORSYTH DOUGLAS | Buy | 15.19K | $12.89 | 195.77K |
| 2024-08-21 | Lappe Mark | Buy | 12.95K | $12.93 | 167.38K |
| 2024-08-20 | Lappe Mark | Buy | 27.05K | $12.97 | 350.90K |
| 2024-06-24 | Kayyem Jon Faiz | Sell | 89.05K | — | — |
| 2024-06-24 | Kayyem Jon Faiz | Buy | 10.00K | — | — |
| 2024-06-05 | Kayyem Jon Faiz | Buy | 8.27K | $17.89 | 147.86K |
| 2024-06-05 | Kayyem Jon Faiz | Buy | 49.28K | $17.23 | 849.16K |
| 2024-06-04 | Kayyem Jon Faiz | Buy | 23.73K | $18.24 | 432.76K |
| 2024-06-04 | Kayyem Jon Faiz | Buy | 65.34K | $17.44 | 1.14M |
| 2024-06-03 | Kayyem Jon Faiz | Buy | 80.74K | $17.90 | 1.45M |
| 2024-06-03 | Kayyem Jon Faiz | Buy | 46.79K | $16.61 | 777.22K |
| 2024-05-31 | Kayyem Jon Faiz | Buy | 70.19K | $16.14 | 1.13M |
| 2024-05-30 | VIKING GLOBAL INVESTORS LP | Sell | 1.04M | $0.00 | 104 |
| 2024-05-30 | VIKING GLOBAL INVESTORS LP | Sell | 511.63K | $30.00 | 15.35M |
| 2024-05-30 | Vuori Kristiina MD | Sell | 15.00K | $12.57 | 188.55K |
| 2024-05-30 | Vuori Kristiina MD | Sell | 30.00K | $40.45 | 1.21M |
| 2024-05-30 | Vuori Kristiina MD | Sell | 15.00K | $23.03 | 345.45K |
| 2024-05-30 | MANHARD KIMBERLY | Sell | 3.50K | $17.44 | 61.04K |
| 2024-05-30 | MANHARD KIMBERLY | Sell | 15.00K | $24.78 | 371.70K |
| 2024-05-30 | MANHARD KIMBERLY | Sell | 15.00K | $23.03 | 345.45K |
| 2024-05-30 | MANHARD KIMBERLY | Sell | 15.00K | $12.57 | 188.55K |
| 2024-05-30 | MANHARD KIMBERLY | Sell | 17.26K | $20.43 | 352.60K |
| 2024-05-30 | Lappe Mark | Sell | 100.00K | $23.30 | 2.33M |
| 2024-05-30 | Lappe Mark | Sell | 59.46K | $30.00 | 1.78M |
| 2024-05-30 | Lappe Mark | Sell | 145.00K | $33.63 | 4.88M |
| 2024-05-30 | Kayyem Jon Faiz | Sell | 17.26K | $10.52 | 181.56K |
| 2024-05-30 | Kayyem Jon Faiz | Sell | 15.00K | $24.78 | 371.70K |
| 2024-05-30 | Kayyem Jon Faiz | Sell | 25.00K | $30.00 | 750.00K |
| 2024-05-30 | Kayyem Jon Faiz | Sell | 15.00K | $23.03 | 345.45K |
| 2024-05-30 | Kayyem Jon Faiz | Sell | 15.00K | $12.57 | 188.55K |
| 2024-05-30 | FORSYTH DOUGLAS | Sell | 15.00K | $12.57 | 188.55K |
| 2024-05-30 | FORSYTH DOUGLAS | Sell | 598.26K | $30.00 | 17.95M |
| 2024-05-30 | FORSYTH DOUGLAS | Sell | 17.26K | $10.52 | 181.56K |
| 2024-05-30 | FORSYTH DOUGLAS | Sell | 15.00K | $23.03 | 345.45K |
| 2024-05-30 | FORSYTH DOUGLAS | Sell | 15.00K | $24.78 | 371.70K |
| 2024-05-30 | Eckelman Brendan P. | Sell | 6.67K | $33.63 | 224.21K |
| 2024-05-30 | Eckelman Brendan P. | Sell | 160.00K | $30.00 | 4.80M |
| 2024-05-30 | Eckelman Brendan P. | Sell | 26.67K | $23.30 | 621.34K |
| 2024-05-30 | Deck Kelly | Sell | 9.17K | $34.16 | 313.14K |
| 2024-05-30 | Deck Kelly | Sell | 14.58K | $33.63 | 490.43K |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 178, holders +31 vs prior quarter. Ownership 91.65%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| MORGAN STANLEY | 1.31M | 44.97K | +3.56% | 123.94M |
| PERCEPTIVE ADVISORS LLC | 1.30M | -144.94K | -10.05% | 122.96M |
| SANOFI | 1.16M | 0 | 0.00% | 109.71M |
| VIKING GLOBAL INVESTORS LP | 1.12M | -313.78K | -21.82% | 106.49M |
| HIGHTOWER ADVISORS, LLC | 870.55K | 351 | +0.04% | 82.48M |
| BANK OF AMERICA CORP /DE/ | 841.14K | 808.46K | +2473.63% | 79.70M |
| BLACKROCK, INC. | 825.97K | 27.07K | +3.39% | 78.26M |
| SCHONFELD STRATEGIC ADVISORS LLC | 697.59K | 442.76K | +173.75% | 66.10M |
| STATE STREET CORP | 640.46K | 89.61K | +16.27% | 60.68M |
| VANGUARD CAPITAL MANAGEMENT LLC | 492.48K | 6.05K | +1.24% | 46.66M |
| WOODLINE PARTNERS LP | 400.89K | 16.46K | +4.28% | 37.98M |
| CAPITAL RESEARCH GLOBAL INVESTORS | 363.05K | -29.80K | -7.58% | 34.40M |
| GOLDMAN SACHS GROUP INC | 338.18K | 271.68K | +408.54% | 32.04M |
| PFM HEALTH SCIENCES, LP | 308.38K | 2.95K | +0.97% | 29.22M |
| SOFINNOVA INVESTMENTS, INC. | 303.10K | -102.93K | -25.35% | 28.72M |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 271.70K | 101.00K | +59.17% | 25.74M |
| PARKMAN HEALTHCARE PARTNERS LLC | 256.95K | 256.95K | New | 24.35M |
| GEODE CAPITAL MANAGEMENT, LLC | 256.18K | 24.67K | +10.65% | 24.28M |
| FIRST TURN MANAGEMENT, LLC | 164.78K | 164.78K | New | 15.61M |
| MILLENNIUM MANAGEMENT LLC | 147.20K | -180.66K | -55.10% | 13.95M |
| CDC FINANCIAL, INC. | 140.13K | 78.13K | +126.02% | 13.28M |
| FIRST TRUST ADVISORS LP | 128.42K | 128.42K | New | 12.17M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 122.56K | 50.10K | +69.14% | 11.61M |
| CAPITOLIS LIQUID GLOBAL MARKETS LLC | 119.20K | -5.80K | -4.64% | 11.29M |
| NORTHERN TRUST CORP | 100.96K | 7.26K | +7.75% | 9.57M |
Earnings and financials
Inhibrx Biosciences Inc. (INBX) trades at $72.73, with a market cap of $1.07B and a trailing P/E of -10.52. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 6667000 | 8391000 | 8595000 | 9093000 | 12808000 | 7125000 | 2192000 | 1800000 | 200000 | 1300000 |
Insights · Dividends · Forecast · Financials · Learn